卫信康: 广东信达（北京）律师事务所关于西藏卫信康医药股份有限公司2024年年度股东大会的法律意见书

Core Viewpoint - The legal opinion issued by Guangdong Xinda (Beijing) Law Firm confirms the legality and validity of the convening and proceedings of the 2024 annual general meeting of shareholders for Tibet Weixin Pharmaceutical Co., Ltd. [2][3][7] Group 1: Meeting Convening and Procedures - The board of directors announced the 2024 annual general meeting on April 26, 2025, detailing the convenor, time, method, and agenda [3][5] - The meeting was held on May 16, 2025, with both on-site and remote video participation options available for shareholders [5][6] - The meeting followed the legal requirements set forth in the Company Law and the rules for shareholder meetings [6][7] Group 2: Attendance and Voting - A total of 98 participants attended the meeting, representing 297,747,235 shares, which is 68.87% of the total voting shares [6][7] - The qualifications of the shareholders and their proxies were verified and deemed valid for participation [6][7] Group 3: Voting Procedures and Results - All proposed resolutions were effectively voted on, with special resolutions requiring a two-thirds majority [7][9] - The voting results were announced immediately, confirming that all resolutions passed with significant majorities [7][9] - Detailed voting results are included in the attached summary table [8][9]